Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
AML
gemtuzumab ozogamicin
induction therapy
intensive therapy
midostaurin
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
09 Apr 2024
09 Apr 2024
Historique:
revised:
15
03
2024
received:
09
02
2024
accepted:
18
03
2024
medline:
9
4
2024
pubmed:
9
4
2024
entrez:
9
4
2024
Statut:
aheadofprint
Résumé
We conducted a phase I trial in newly diagnosed acute myeloid leukaemia (AML) to investigate the combination of two novel targeted agents, gemtuzumab ozogamicin (GO) and midostaurin, with intensive chemotherapy in FLT3-mutated AML and CBF leukaemia. Three dose levels of midostaurin and one to three sequential doses of 3 mg/m
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Pfizer
Organisme : Novartis
Informations de copyright
© 2024 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464.
Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open‐label, phase III ALFA‐0701 trial. Haematologica. 2019;104(1):113–119.
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377.
Fournier E, Duployez N, Ducourneau B, Raffoux E, Turlure P, Caillot D, et al. Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. Blood. 2020;135(8):542–546.
Haubner S, Perna F, Köhnke T, Schmidt C, Berman S, Augsberger C, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33(1):64–74.
Ehninger A, Kramer M, Röllig C, Thiede C, Bornhäuser M, von Bonin M, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;4(6):e218.
Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, et al. Adding dasatinib to intensive treatment in core‐binding factor acute myeloid leukemia‐results of the AMLSG 11‐08 trial. Leukemia. 2018;32(7):1621–1630.
Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase i cancer clinical trials. J Natl Cancer Inst. 2009;101(10):708–720.
Storer BE. An evaluation of phase I clinical trial designs in the continuous dose‐response setting. Stat Med. 2001;20(16):2399–2408.
Russell N, Cumming O, Othman J, Dillon R, Potter N, Wilhelm‐Benartzi C, et al. Stev. Gemtuzumab‐based induction chemotherapy combined with midostaurin for FLT3 mutated AML. Updated toxicity and interim survival analysis from the NCRI AML19V2 “MIDOTARG” pilot trial. HemaSphere. 2023;7(S3):814.
Weinbergerová B, Čerňan M, Kabut T, Semerád L, Podstavková N, Szotkowski T, et al. Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3‐mutated acute myeloid leukemia patients—Czech center experience. Haematologica. 2023;108:2826–2829.